Yo-yo dieter Bev Thomas, 53, from Port Talbot, Wales, lost six stone in six months on weight loss drug Mounjaro after her ...

Pharmaceutical giant Novo Nordisk (NYSE: NVO) released its fourth-quarter and full-year earnings report on Feb. 5. The Denmark-based company performed pretty well, leading to a post-earnings jump in ...

New research supports what some people taking the blockbuster weight loss drug semaglutide – better known by the brand names Ozempic and Wegovy – have experienced: that it eases alcohol ...

Medjool dates are paired with warm cinnamon, almond butter, cashews, oats, vanilla, and a dash of salt to make these breakfast-worthy bites. All ingredients come together in just 10 minutes to ...

But the results add to evidence from animal studies and reports that people are finding drugs like Ozempic and Wegovy helpful to manage cravings, not just for food, but also for tobacco and alcohol.

The study, completed by scientists at the University of Southern California, confirms anecdotal reports that Ozempic and Wegovy users were getting fewer cravings for alcohol. Scientists at the ...

GLP-1 drugs — which include Ozempic and its sister drug Wegovy, as well as Mounjaro and Zepbound — mimic at least one hormone produced by the gut to signal fullness, leading to a reduced appetite.

COPENHAGEN--Novo Nordisk will launch its hugely popular anti-obesity drug Wegovy in Japan on Feb. 22 next year, its first launch in Asia, the company said on Thursday, even as it struggles to keep ...

The fourth season won't air until 2026 but will centre on the love story of Benedict Bridgerton, played by Luke Thompson, 36, ...

Novo Nordisk’s breakneck sales growth has continued in the first quarter of this year with a 24% increase that was helped by a doubling in turnover of obesity blockbuster Wegovy. Group revenues ...

The first clinical trial of its kind found the weekly jab semaglutide, also known as Ozempic and Wegovy, cuts the amount people drink in one day by about 40% and dramatically reduced the desire ...

Within Novo Nordisk's comprehensive business update to investors, attention latched onto early data for an oral obesity therapy that outperformed the company’s big-selling GLP-1 agonist Wegovy ...